Cargando…
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate (ADC), combining a humanized monoclonal antibody (IgG1) targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and a potent cytotoxic maytansinoid derivative, DM4, inhibiting microtubule assembly. SAR408701 is cu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098589/ https://www.ncbi.nlm.nih.gov/pubmed/35166967 http://dx.doi.org/10.1007/s10928-021-09799-0 |
_version_ | 1784706419304431616 |
---|---|
author | Pouzin, Clemence Gibiansky, Leonid Fagniez, Nathalie Chadjaa, Mustapha Tod, Michel Nguyen, Laurent |
author_facet | Pouzin, Clemence Gibiansky, Leonid Fagniez, Nathalie Chadjaa, Mustapha Tod, Michel Nguyen, Laurent |
author_sort | Pouzin, Clemence |
collection | PubMed |
description | Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate (ADC), combining a humanized monoclonal antibody (IgG1) targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and a potent cytotoxic maytansinoid derivative, DM4, inhibiting microtubule assembly. SAR408701 is currently in clinical development for the treatment of advanced solid tumors expressing CEACAM5. It is administered intravenously as a conjugated antibody with an average Drug Antibody Ratio (DAR) of 3.8. During SAR408701 clinical development, four entities were measured in plasma: conjugated antibody (SAR408701), naked antibody (NAB), DM4 and its methylated metabolite (MeDM4), both being active. Average DAR and proportions of individual DAR species were also assessed in a subset of patients. An integrated and semi-mechanistic population pharmacokinetic model describing the time-course of all entities in plasma and DAR measurements has been developed. All DAR moieties were assumed to share the same drug disposition parameters, excepted for clearance which differed for DAR0 (i.e. NAB entity). The conversion of higher DAR to lower DAR resulted in a DAR-dependent ADC deconjugation and was represented as an irreversible first-order process. Each conjugated antibody was assumed to contribute to DM4 formation. All data were fitted simultaneously and the model developed was successful in describing the pharmacokinetic profile of each entity. Such a structural model could be translated to other ADCs and gives insight of mechanistic processes governing ADC disposition. This framework will further be expanded to evaluate covariates impact on SAR408701 pharmacokinetics and its derivatives, and thus can help identifying sources of pharmacokinetic variability and potential efficacy and safety pharmacokinetic drivers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10928-021-09799-0. |
format | Online Article Text |
id | pubmed-9098589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-90985892022-05-14 Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate Pouzin, Clemence Gibiansky, Leonid Fagniez, Nathalie Chadjaa, Mustapha Tod, Michel Nguyen, Laurent J Pharmacokinet Pharmacodyn Original Paper Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate (ADC), combining a humanized monoclonal antibody (IgG1) targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and a potent cytotoxic maytansinoid derivative, DM4, inhibiting microtubule assembly. SAR408701 is currently in clinical development for the treatment of advanced solid tumors expressing CEACAM5. It is administered intravenously as a conjugated antibody with an average Drug Antibody Ratio (DAR) of 3.8. During SAR408701 clinical development, four entities were measured in plasma: conjugated antibody (SAR408701), naked antibody (NAB), DM4 and its methylated metabolite (MeDM4), both being active. Average DAR and proportions of individual DAR species were also assessed in a subset of patients. An integrated and semi-mechanistic population pharmacokinetic model describing the time-course of all entities in plasma and DAR measurements has been developed. All DAR moieties were assumed to share the same drug disposition parameters, excepted for clearance which differed for DAR0 (i.e. NAB entity). The conversion of higher DAR to lower DAR resulted in a DAR-dependent ADC deconjugation and was represented as an irreversible first-order process. Each conjugated antibody was assumed to contribute to DM4 formation. All data were fitted simultaneously and the model developed was successful in describing the pharmacokinetic profile of each entity. Such a structural model could be translated to other ADCs and gives insight of mechanistic processes governing ADC disposition. This framework will further be expanded to evaluate covariates impact on SAR408701 pharmacokinetics and its derivatives, and thus can help identifying sources of pharmacokinetic variability and potential efficacy and safety pharmacokinetic drivers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10928-021-09799-0. Springer US 2022-02-15 2022 /pmc/articles/PMC9098589/ /pubmed/35166967 http://dx.doi.org/10.1007/s10928-021-09799-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Pouzin, Clemence Gibiansky, Leonid Fagniez, Nathalie Chadjaa, Mustapha Tod, Michel Nguyen, Laurent Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate |
title | Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate |
title_full | Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate |
title_fullStr | Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate |
title_full_unstemmed | Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate |
title_short | Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate |
title_sort | integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a dm4 anti-ceacam5 antibody-drug conjugate |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098589/ https://www.ncbi.nlm.nih.gov/pubmed/35166967 http://dx.doi.org/10.1007/s10928-021-09799-0 |
work_keys_str_mv | AT pouzinclemence integratedmultipleanalytesandsemimechanisticpopulationpharmacokineticmodeloftusamitamabravtansineadm4anticeacam5antibodydrugconjugate AT gibianskyleonid integratedmultipleanalytesandsemimechanisticpopulationpharmacokineticmodeloftusamitamabravtansineadm4anticeacam5antibodydrugconjugate AT fagnieznathalie integratedmultipleanalytesandsemimechanisticpopulationpharmacokineticmodeloftusamitamabravtansineadm4anticeacam5antibodydrugconjugate AT chadjaamustapha integratedmultipleanalytesandsemimechanisticpopulationpharmacokineticmodeloftusamitamabravtansineadm4anticeacam5antibodydrugconjugate AT todmichel integratedmultipleanalytesandsemimechanisticpopulationpharmacokineticmodeloftusamitamabravtansineadm4anticeacam5antibodydrugconjugate AT nguyenlaurent integratedmultipleanalytesandsemimechanisticpopulationpharmacokineticmodeloftusamitamabravtansineadm4anticeacam5antibodydrugconjugate |